12 results about "Cytokine storm" patented technology

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The at least one hairpin loop structure is formed by one or more short hairpin RNA sequences. The at least one hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The first promoter is disposed upstream of the at least one hairpin loop structure.

The present disclosure relates to methods of treating Coronavirus-Associated Lung Damage (CALD) and cytokine storm using CALD-treating compounds. The methods can involve administering CALD-treating compounds to a patient suffering from CALD or cytokine storm.

This invention relates to the field of biomedicine, specifically to the combined application of interferon-alpha (IFN-α) and NF-κB signaling pathway inhibitors, particularly the application of interferon-alpha combined with bortezomib in the preparation of drugs for the prevention and / or treatment of viral infections. Host-produced lactate is a key microenvironmental factor driving the shift of IFN-α from "anti-inflammatory" to "pro-inflammatory." Lactic acid, in conjunction with IFN-α, excessively activates the NF-κB signaling pathway, thereby triggering a cytokine storm. Based on this novel mechanism, this invention creatively proposes the combined use of IFN-α and bortezomib. This combination effectively blocks lactate / IFN-α-induced NF-κB overactivation, retaining the potent antiviral activity of IFN-α while completely reversing its side effect of exacerbating inflammation in the later stages of viral infection, achieving a dual effect of "antiviral" and "inflammatory control."

Disclosed are glycan compounds and their use for treating or inhibiting the development of a viral infection, in particular a coronavirus infection, such as a SARS-CoV-2 infection, in a subject, or for treating a condition associated with a viral infection, such as an acute inflammatory condition, cytokine release syndrome (CRS) or cytokine storm, severe acute respiratory syndrome (SARS) or acute respiratory distress syndrome (ARDS).

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure and a first promoter. The hairpin loop structure regulates an amount of Interleukin 6 (IL6) cytokine during immunotherapy. The hairpin loop structure is formed by at least two short hairpin RNA sequences and at least one microRNA30 sequence. The short hairpin RNA sequences form a stem of the hairpin loop structure. The microRNA30 sequence forms a loop of the hairpin loop structure. The first promoter is disposed upstream of the hairpin loop structure.

The invention relates to an IL-10 armed immune cell with an inhibited IFN-gamma function and application of the IL-10 armed immune cell. The protein expressed by the immune cell comprises CAR containing an antigen recognition domain and IL-10; the immune cell expresses a single-chain antibody (scFv) capable of recognizing IFN-gamma and / or an IFN-gamma gene locus, and the function of the IFN-gamma is inhibited by inserting a CAR and / or IL-10 gene at a fixed point. As the function of IFN-gamma is inhibited, the immune cell constructed in the invention can significantly reduce the content of inflammatory cytokines, thereby reducing the side effects of cytokine storm, neurotoxicity and the like in immune cell therapy.

The present disclosure relates to a bispecific antibody and use thereof. The bispecific antibody or antigen-binding fragment thereof comprises: (a) a first antigen-binding moiety or antigen-binding fragment thereof, the first antigen-binding moiety comprising a first light chain and a first heavy chain, the first light chain being a kappa type light chain, the first antigen-binding moiety comprising a first binding domain that binds to a first antigen; and (b) a second antigen-binding moiety or antigen-binding fragment thereof, the second antigen-binding moiety comprising a second light chain and a second heavy chain, the second light chain being a lambda type light chain, the second antigen-binding moiety comprising a second binding domain that binds to a second antigen. The bispecific antibody has a low mispairing rate of heavy and light chains, a high yield in purification, does not bind to Fc gamma R receptors, reduces the risk of cytokine storm, is well tolerated, and has better efficacy and safety than antibodies of the same kind.

This application belongs to the field of biomedical technology, specifically providing the application of human activated NK cells in the preparation of drugs for treating systemic juvenile idiopathic arthritis. Human activated NK cells derived from umbilical cord blood are intravenously infused at an optimal regimen of 3×10⁶-5×10⁶ cells / individual, once every 3 days for a total of 2 times. This significantly reduces the levels of IL-6, TNF-α, and SAA in the sJIA model, alleviates joint swelling, promotes weight recovery, reduces spleen index, and inhibits cytokine storm. The therapeutic effect can be maintained for at least 14 days without rebound. It has high safety, no obvious liver and kidney damage, and is suitable for clinical translational application.

The present invention provides a chimeric antigen receptor based on the intracellular domain, comprising sequentially linked extracellular domains, transmembrane domains, and intracellular domains, wherein the extracellular domain comprises an antigen recognition region and a hinge region, and the intracellular domain comprises sequentially linked CD3ε intracellular domain cleavage, a co-stimulatory signaling region, and a CD3ζ intracellular domain. Compared to prior art, the provided chimeric antigen receptor exhibits superior therapeutic effects and fewer side effects, as reflected in improved membrane surface CAR molecule levels of CAR-T cells, better immune synapse formation, superior antigen sensitivity, fewer cytokines, better growth capacity, better sustained proliferation capacity, better repeated killing capacity, reduced NK cell activation and cell depletion, and an increase in stem cell-like and memory cell subsets of CAR-T cells. Furthermore, the chimeric antigen receptor can further enhance the therapeutic effect on tumors and, at the same time, reduce the production of inflammatory cytokines associated with the activation of macrophages and monocytes by downregulating its own cytokines, thereby enabling early prevention of cytokine storms.

The present invention provides a pharmaceutical composition for use in treating, improving, or preventing acute respiratory diseases or conditions or cytokine storms in subjects requiring such treatment. [Solution] A pharmaceutical composition containing an effective amount of conditioned medium (CM) derived from mesenchymal stem cells (MSCs) that have been exposed to chemotherapy.

Provided is a recombinant cell, which contains a chimeric antigen receptor and an shRNA that inhibits the life cycle of HIV in a targeted manner. Further provided are a chimeric antigen molecule and a recombinant cell containing the above-mentioned chimeric antigen molecule cell, wherein an extracellular region of the chimeric antigen molecule is derived from or contains an extracellular region of a human CD4 molecule, and a transmembrane region of the chimeric antigen molecule is derived from or contains a transmembrane domain of CD8α. The above-mentioned recombinant cell can be used for treating HIV infection, and can have a stronger comprehensive killing effect, longer effective time and less risk of causing a cytokine storm in the environment of HIV infection.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop structure, at least one second hairpin loop structure and a first promoter. The first and second hairpin loop structure regulates an amount of Granulocyte monocyte colony stimulating factor (GMCSF) cytokine and Interleukin 6 (IL6) cytokine, respectively. The first hairpin loop structure is formed by at least two first short hairpin RNA sequences and at least one microRNA30 sequence. The second hairpin loop structure is formed by at least two second short hairpin RNA sequences and at least one microRNA30 sequence. The first promoter is disposed upstream of the first and second hairpin loop structure.